Health Informatics And Implementation Science
Biostatistics And Health Services Research
Fiocruz-Minas Caroline Junqueira, PhD - Staff Scientist Camila Brabosa, PhD student - Mapping of CD8 T cell-specifc Epitopes from Malaria Blood Stage Gregorio Almeida, DVM, PhD - Immunology of Asymptomatic Malaria Guilherme Maia, PhD - Innate Lymphocytes in Malaria Isabella Hirako, PhD - Monocyte-Derived Dendritic Cells in Malaria Júlia Castro, MSc student - Chagas Disease Vaccine Larissa Pereira, MSc student - Inflammatory Caspases in Malaria Kely Mateucci, PhD - Monocyte-Derived Dendritic Cells Metabolism in Malaria Milton Pereira, PhD - Caspases and inflammasomes in Malaria and Chagas Disease Natalia Satchiko Souza, PhD - CD8+ T cells in malaria UMASS Danielle Durso, PhD - IRAKs and Myddosomes in host resistance to T. gondii Patricia Assis, PhD - Host Clock genes and Malaria Ogooluwa Ojelabi, PhD - Glucose Metabolism and Malaria
Elisabeth Chair for the Dean of Medicine
Cutler Chair in Vascular and Endovascular Surgery
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Joy McCann Professor for Women in Medicine
Background for Student Rotation Projects <p >See Politz, Hogan and Pederson (2009) and Politz et al. (2005) in the above list. The novel microRNA work may be the most suitable for student rotations. Potential Rotation Projects <p >Are the nucleolar microRNAs pri-, pre- or mature? <p >Are they complexed with other nucleolar RNAs? <p >Do the cell cycle related proteins in the nucleolus exist as heterotypic complexes? <p >Does the nucleolus of human embryonic stem cells also share these features (which we have so far looked for, and found, only in transformed human cell lines)? <p >Can vanadium tagging be used to detect specific proteins by electron microscopy, perhaps exceeding the limitations of immuno-EM?
Lambi and Sarah Adams Chair in Genetic Research
Rotations: Targeting the IFN-?-chemokine axis for treatment of vitiligo: We are using our newly developed mouse model and human tissues from patients with vitiligo to identify the cytokines and chemokines that are expressed within the depigmenting skin and which skin cells produce them. We are using genetically modified mouse strains (knockouts, conditional knockouts, fluorescent reporter strains), and cytokine and chemokine neutralizing antibodies to identify the key proteins required for disease. This data will permit us to rationally develop and test new therapeutic agents. Understanding the proinflammatory signals generated by melanocytes under cellular stress. Melanocytes from vitiligo patients have intrinsic abnormalities, including cellular stress evidenced by increased production of reactive oxygen species (ROS) and activation of the unfolded protein response (UPR). The immune system has evolved to recognize this stress as damage-associated molecular patterns (DAMPs), which activate innate immunity. We are using human cells and tissues to determine how cellular stress, innate immunity, and adaptive immunity cooperate to initiate and perpetuate depigmentation in vitiligo. Developing a humanized mouse model of immune-skin interactions to serve as a pre-clinical bridge to clinical studies: We are developing a humanized mouse model of skin disease that consists of an immunodeficient mouse strain as a host for an autologous human skin graft and immune reconstitution in order to study mechanisms of inflammation in the skin, including allergic contact dermatitis, response to infection, tumor immunotherapy, and autoimmunity, all within a fully human environment. This model system will act as a pre-clinical bridge between mouse models and human clinical trials, providing an opportunity to test new treatments on human cells and tissues prior to initiating trials on patients. Tracking real-time autoreactive T cell migration and interactions within the skin: We are using fluorescently/bioluminescently tagged CD8 T cells to track their movements and interactions within the skin in live mice, using real-time confocal microscopy and bioluminescent imaging. Initial studies will focus on the role of cytokines and chemokines in T cell migration within the skin. Clinical trial to test a novel treatment for vitiligo: We are in the early stages of developing a clinical trial based on insights developed from our animal data to test a novel drug for its ability to treat vitiligo.
Rotations: Targeting the IFN-g-chemokine axis for treatment of vitiligo: We are using our newly developed mouse model and human tissues from patients with vitiligo to identify the cytokines and chemokines that are expressed within the depigmenting skin and which skin cells produce them. We are using genetically modified mouse strains (knockouts, conditional knockouts, fluorescent reporter strains), and cytokine and chemokine neutralizing antibodies to identify the key proteins required for disease. This data will permit us to rationally develop and test new therapeutic agents. Understanding the proinflammatory signals generated by melanocytes under cellular stress. Melanocytes from vitiligo patients have intrinsic abnormalities, including cellular stress evidenced by increased production of reactive oxygen species (ROS) and activation of the unfolded protein response (UPR). The immune system has evolved to recognize this stress as damage-associated molecular patterns (DAMPs), which activate innate immunity. We are using human cells and tissues to determine how cellular stress, innate immunity, and adaptive immunity cooperate to initiate and perpetuate depigmentation in vitiligo. Developing a humanized mouse model of immune-skin interactions to serve as a pre-clinical bridge to clinical studies: We are developing a humanized mouse model of skin disease that consists of an immunodeficient mouse strain as a host for an autologous human skin graft and immune reconstitution in order to study mechanisms of inflammation in the skin, including allergic contact dermatitis, response to infection, tumor immunotherapy, and autoimmunity, all within a fully human environment. This model system will act as a pre-clinical bridge between mouse models and human clinical trials, providing an opportunity to test new treatments on human cells and tissues prior to initiating trials on patients. Tracking autoreactive T cell interactions within the skin: We are using fluorescently tagged CD8 T cells to track their cellular interactions within the skin using confocal microscopy. Future studies will adapt this model to investigate real-time migration and other movements of these cells within compartments of the skin. Clinical trial to test a novel treatment for vitiligo: We recently completed a clinical trial based on insights developed from our animal data to test a novel drug for its ability to treat vitiligo.
Interests: Vitiligo, autoimmunity, immunology, translational research
Barbara Helen Smith Chair in Preventive & Behavioral Medicine
Interests: Pediatric dermatology, psoriasis, genodermatoses, medical dermatology, inpatient dermatology
Richard M. Haidack Professor in Medicine
Research in Dr. Koupenova's lab focuses on the contribution of platelets to the immune response during viral infection and the consequent implications of that response to cardiovascular disease. For additional information about projects or joining the lab, contact Dr. Koupenova @ milka.koupenova@umassmed.edu
Interests: Autoimmunity, Immunology, Fibrosis, Translational Research, Lupus
Dr. John Meyers Professor in Primary Care Medicine
Population and Quantitative Health Sciences
Biochemistry and Molecular Biotechnology
Prevention Research Center at UMass Chan
Tweets by @DrSherryPagoto
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Myles J. McDonough Chair in Rheumatology
Susan D Moffatt-Bruce MD, PhD, FRCSC, MBOE, MBA,FACS
Sourbha S Dani MD, MSc, GDCE, CCDS, FACC,FACP
Joseph D. Early Chair in Biomedical Research
Dr. Wilcox trained in EM at the Harvard Affiliated EM Residency, then completed an Anesthesia Critical Care fellowship. In addition to the ED, she has attended in Surgical, Medical, and Cardiac ICUs. She joined Lahey Hospital in 2022 as the Medical Director of the 5C Medical ICU. She is Vice Chair for Academic Affairs and a Professor of Medicine. She is the Associate CMO for Boston MedFlight.
EMCrit 181 – Pulmonary Hypertension and Right Ventricular Failure with Susan Wilcox
HarvardX: Mechanical Ventilation for COVID-19
CritCases 7 Pulmonary Hypertension – A Fine Balance
Academic Life in Emergency Medicine: The Myth of Vasopressors and Ischemia
ACEP COVID-19 Field Guide: ICU Care in the Emergency Department
Podcast summary of articles from the June 2021 edition of the Journal of Emergency Medicine